F S&P 500
5,566.50 +20.50 (+0.37%) F Dow Jones
39,583.00 +33.00 (+0.08%) F Nasdaq
20,129.50 +90.00 (+0.45%) E-mini Russell 2000 Index Futur
2,075.60 +15.50 (+0.75%) Petróleo
82.36 +0.62 (+0.76%) Oro
2,346.00 +9.40 (+0.40%)
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc.
80 Guest Street
Suite 601
Boston, MA 02135
United States
(617) 500-8099
https://www.compasstherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 32
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Thomas J. Schuetz M.D., Ph.D. | Chief Executive Officer | 835.88k | N/D | 1961 |
| Dr. Vered Bisker-Leib M.D., MBA, Ph.D. | Senior Consultant | 719k | N/D | 1971 |
| Mr. Neil L. Lerner CPA | Vice President of Finance | N/D | N/D | 1967 |
| Mr. Jonathan Anderman J.D. | VP, Head of Legal & Corporate Secretary | N/D | N/D | N/D |
| Anna Gifford | Communications Manager | N/D | N/D | N/D |
| Dr. Minori Rosales M.D., Ph.D. | Senior VP & Head of Clinical Development | N/D | N/D | 1963 |
| Ms. Karin Herrera B.A. | VP & Head of Clinical Operations | N/D | N/D | N/D |
| Dr. James Kranz Ph.D. | VP and Head of Chemistry Manufacturing & Controls | N/D | N/D | N/D |
Descripción
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Compass Therapeutics, Inc. a partir del 1 de junio de 2024 es 7. Las puntuaciones principales son Auditoría: 3; Junta: 7; Derechos del accionista: 8; Compensación: 9.
